A Phase 1/2 open label study of Nivolumab monotherapy or Nivolumab combined with Ipilimumab in subjects with advanced or metastatic solid tumors.

Administered By

Awarded By

Contributors

Start/End

  • April 1, 2014 - March 31, 2022